Clinical Trials Browser

Phase 2 × Carcinoma, Non-Small-Cell Lung × dalotuzumab × Clear all

NCT00654420 2018-08-08

A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

Phase 2 Completed

95 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT00951444 2016-07-06

Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00799240 2014-11-07

IMPACT

Phase 2 Completed

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion